anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention herein pertains to methods and materials for producing a nicotine maintenance pouch. Laminates comprising a nicotine barrier layer and a nicotine degradation agent barrier layer are disclosed. In a preferred embodiment, the nicotine barrier layer comprises a nitrile rubber modified acrylonitrilemethyl acrylate copolymer. An especially preferred nicotine barrier material comprises, by weight percent, 75% acrylonitrile, and 25% methyl acrylate with 10% butadiene (AN-MA/B). The nicotine degradation agent barrier layer is preferably aluminum foil. In an especially preferred embodiment, the laminate comprises a layer of AN-MA/B adhered to a layer of aluminum foil, which in turn is adhered to a layer of paper stock. Pouches comprising a self-sealed nicotine barrier layer and a nicotine degradation agent barrier layer are disclosed. These pouches are preferably formed from the laminates above. A method for production of pouches comprises: (a) providing a laminate including a self-sealable nicotine barrier layer and a nicotine degradation agent barrier layer; and (b) sealing the self-sealable nicotine barrier layer to enclose a nicotine device.
Placebo will be 2g of powdered cellulose, to be taken daily alongside usual diet for 24 weeks. Placebo will be 2g of powdered cellulose, to be taken daily alongside usual diet for 24 weeks.
PURPOSE:To obtain a deodorizing composition containing a bile acid salt as an active ingredient, having proliferation suppressing effect of bad causative bacterium and high safety and capable of suppressing body odor without side effects. CONSTITUTION:The aimed composition containing a bile acid salt as an active ingredient. The bile acid salt includes deoxycholic acid, alkali metal salt (preferably sodium or potassium salt) of cholic acid or the both thereof. The content of bile acid salt blended in the composition is 0.1-5wt.%, preferably 0.5-3wt.% based on total weight of the composition. As other ingredients other than the bile acid salt, various additives, solvent, etc., can be properly selected and blended according to the purpose. A solvent for bile acid salt includes water, alcohol, etc., preferably ethyl alcohol, e.g. ethyl alcohol having 70wt.% concentration or isopropyl alcohol, e.g. isopropyl alcohol having 30wt.% concentration.
Augentropfen Stulln Mono Eye Drops (Stulln eyedrops) will be provided to participants in individual single-use vials. Participants will apply the drops to the two eyes 3 times a day, six days a week before sustained eye use (except Sunday).
In Part 1 subjects will be assigned to escalation cohort of the doublet of dabrafenib and panitumumab based on the monotherapy doses of dabrafenib (150 milligrams \[mg\] twice daily) and panitumumab (6 milligrams per kilogram \[mg/kg\] every-2-week \[Q2W\]). Dose escalation will follow a 3+3 dose escalation procedure. If the initial combination dose of dabrafenib and panitumumab in Cohort 1 (starting dose) is not tolerable, lower dose combination(s) may be evaluated.
PCT No. PCT/FR81/00134 Sec. 371 Date Jun. 23, 1982 Sec. 102(e) Date Jun. 23, 1982 PCT Filed Oct. 22, 1981 PCT Pub. No. WO82/01468 PCT Pub. Date May 13, 1982.A new galenic form with delayed release of METROCLOPRAMIDE, useful for gastric treatment, is formed by microgranules comprising a neutral core formed by a grain of an inert excipient comprising at least two components of the type belonging to the class formed by saccharose, starch, talc, desiccating silica, lactose and stearic acid, this neutral grain being provided with a first layer comprising METOCLOPRAMIDE, then a second outer layer formed by a microporous envelope comprising at least one natural and/or synthetic polymer belonging to the class formed by shellac, gum arabic, ethyl cellulose, cellulose acetophtalate, cellulose triacetate, polyoxyethyleneglycol, the methacrylates, styrene-acrylonitrile copolymer and polyvinylpyrrolidone in successive envelopes.
There are different variables that may influence the occurrence of chronic pain after childbirth. One of these could be c- section , pain status before childbirth or other psychological factors like fear of birth, irrational cognitive beliefs about delivery and perinatal complications. The pain status (intensity and location), demographic data, anesthesiological details and data about the circumstances of birth are evaluated by structured interview during pregnancy and 3 month and 12 moth after childbirth. The pregnant women received an individual code for access to the survey on the website of the study. The recruitment takes placed in doctors or midwifes office and by advertising. The commuting area was the city of Tuebingen (Germany). Women who feel uncomfortable with the media based survey supplied a written form. Study population is planned with 500 participants. The Institute for Clinical Epidemiology and Applied Biometry support the statistical analysis.
Antimicrobial peptides enable an alternate approach to developing antimicrobial coatings due to their targeting of the membranes of the bacteria. High specific activity is achieved by orienting the peptides so that the antimicrobial ends of the peptides maximally contact the bacteria. In one embodiment, one end of the peptide is covalently attached directly to the substrate. In another embodiment, the peptides are immobilized on the substrate using a coupling agent or tether. Non-covalent methods include coating the peptide onto the substrate or physiochemically immobilizing the peptides on the substrate using highly specific interactions, such as the biotin/avidin or streptavidin system. The compositions are substantially non-leaching, antifouling, and non-hemolytic. The immobilized peptides retain sufficient flexibility and mobility to interact with and de endocytosed by the bacteria, viruses, and/or fungi upon exposure. Immobilizing the peptides to the substrate reduces concerns regarding toxicity of the peptides and the development of antimicrobial resistance, while presenting substantially all of the peptide at the site of action at the surface of the substrate.
The combination of a QTL on chromosome arm 4BL and Yr29 provides durable resistance with no significant yield penalty. Wheat stripe rust or yellow rust (YR), caused by Puccinia striiformis f. sp. tritici (Pst), causes substantial yield reductions globally, but losses can be minimized by using resistance genes. Chinese wheat cultivar Jing 411 (J411) has continued to display an acceptable level of adult-plant resistance (APR) to YR in varied field conditions since its release in the 1990s. A recombinant inbred line (RIL) population comprising 187 lines developed from a cross of J411 and Kenong 9204 (KN9204) was evaluated in multiple environments to identify genomic regions carrying genes for YR resistance. A total of five quantitative trait loci (QTL) on chromosome arm 1BL, 3BS, 4BL, 6BS, and 7BL from J411 and two QTL on 3DS and 7DL from KN9204 were detected using inclusive composite interval mapping with the wheat 660 K SNP array. QYr.nwafu-1BL.5 and QYr.nwafu-4BL.3 from J411 were robust and showed similar effects in all environments. QYr.nwafu-1BL.5 was likely the pleiotropic gene of Yr29/Lr46. QYr.nwafu-4BL.3 was located within a 1.0 cM interval delimited by KASP markers AX-111609222 and AX-89755491. Based on haplotype analysis, Yr29 and QYr.nwafu-4BL.3 were identified as genetic components of quantitative resistance in a number of wheat cultivars. Moreover, RILs with Yr29 and QYr.nwafu-4BL.3 individually or when combined showed higher resistance to YR in rust nurseries compared with RILs without them, and there was no negative effect of their presence on agronomic traits under rust-free conditions. These results suggest that effective polymerization strategy is important for breeding high yielding and durable resistance cultivars.
BACKGROUND: In polypectomy with mechanical hysteroscopic morcellators, the tissue removal procedure continues until no polyp tissue remains. The decision that the polypoid tissues were removed completely is made based on visual evaluation. In a situation where the polyp tissue was visually completely removed and no doubt that the polyp has been completely removed, short spindle-like tissue fragments on the polyp floor continue in most patients. There are no studies in the literature on whether visual evaluation provides adequate information at the cellular level in many patients in whom polypoid tissues have been determined to be completely removed. The aim of the present study was to analyze the pathological results of the curettage procedure, which was applied following the completion of polyp removal with operative hysteroscopy, and to evaluate whether there was residual polyp tissue in the short spindle-like tissue fragments that the mechanical hysteroscopic morcellator could not remove. The secondary aims of this study were to compare conventional loop resection hysteroscopy with hysteroscopic morcellation for the removal of endometrial polyps in terms of hemoglobin/hematocrit changes, polypectomy time and the amount of medium deficit.
METHODS: A total of 70 patients with a single pedunculate polypoid image of 1.5-2 cm, which was primarily visualized by office hysteroscopy, were included in the study. Patients who had undergone hysteroscopic polypectomy were divided into two groups according to the surgical device used: the morcellator group (n = 35, Group M) and the resectoscope group (n = 35, Group R). The histopathological results of hysteroscopic specimens and curettage materials of patients who had undergone curettage at the end of operative hysteroscopy were evaluated. In addition, the postoperative 24th hour Hb/HCT decrease amounts in percentage, the polypectomy time which was measured from the start of morcellation, and deficit differences were compared between groups.
RESULTS: In total, 7 patients in the morcellator group had residual polyp tissue detected in the full curettage material. The blood loss was lower in the morcellator group than in the resectoscope group (M, R; (-0.07 ± 0.08), (-0,11 ± 0.06), (p < 0.05), respectively). The deficit value of the morcellator group were higher (M, R; (500 ml), (300 ml), (p < 0.05), respectively). The polypectomy time was shorter in the morcellator group (M, R; mean (2.30 min), (4.6 min), (p < 0.05)).
CONCLUSIONS: Even if the lesion is completely visibly removed during hysteroscopic morcellation, extra caution should be taken regarding the possibility of residual tissue. There is a need for new studies investigating the presence of residual polyp tissue.
The study group of 30 patients ASA status 2 or 3 received 8 mg of dexamethasone with 12,5 mg of 0,5% of levobupivacaine intrathecally for surgical reconstruction of proximal femoral fracture. Spinal anaesthesia was performed in sitting position using middle approach in intervertebral space L2-L3 or L3-L4 with spinal needles 22-27 GA.
Generating real-time trigger-based digital feed is provided. A system receives events indicating modifications for candidate electronic transactions. The system selects a participant object including a support service identifier. The system filters the events based on a metric. The system ranks the opportunity objects based on a second metric. The system receives a selection of a ranked opportunity object, and generate a link.
The invention relates to an anti-oxidation peptide anti-NV of rana ventricosa (Nanorana ventripunctata) skin and a gene and application thereof, belonging to the field of biomedicine. The skin antioxidant peptide anti-NV is a polypeptide coded by a quasipaa ventricosa defending peptide gene of a special species of Chinese amphibian, has a molecular weight of 1963.7 daltons, an isoelectric point of 9.31, and an amino acid sequence of the polypeptide is shown as SEQ ID NO. 1. The gene for encoding the bullfrog skin antioxidant peptide anti-NV precursor consists of 299 nucleotide sequences, and the nucleotide sequences are shown in SEQ ID NO. 2; wherein the 156 th to 216 th nucleotide is the coding gene of mature bullfrog skin antioxidant peptide anti-NV. The application of the bullfrog skin antioxidant peptide anti-NV in preparing the anti-skin photoaging therapeutic drug. The beneficial effects are that: has strong skin photoaging resistance and can obviously inhibit the occurrence of skin photoaging.
Thirty patients were recruited having met the following inclusion criteria of (1) good general health, (2) good periodontal health, (3) caries-free, (4) good oral hygiene. The subjects were divided into 3 groups based on a radiographic assessment on the level of root resorption; normal (no root resorption), mild (less than 2 mm), and severe (more than 2 mm). The GCF samples were taken from the permanent central incisors of untreated subjects in the normal control group (n=14), while in the mild group, samples were collected from the permanent central incisors with mild root resorption (\<2 mm) in patients undergoing active orthodontic treatment after 6 months with radiographic evidence (mild group, n=5). Child patients with severe root resorption (\>2 mm) were those with primary second molars undergoing physiological root resorption (severe group, n=11). The GCF samples were collected from the mesial and the distal gingival crevicular sulcus of the involved teeth using gingival fluid collection strips (Periopaper, Oraflow, Smithtown, N.Y.). The paper strips were placed within the sulcus (intrasulcular method) approximately 1 to 2 mm into the gingival sulcus and left in situ for 60 seconds. Every sample collection was taken 3 times at the same site with one-minute resting intervals to allow GCF to be replenished into the gingival sulcus.
1,268,115. Dental filling materials. JOHNSON & JOHNSON. 13 June, 1969 [14 June, 1968], No. 30149/69. Heading C3P. Packaged dental filling materials for preparing cured dental fillings comprise a two-part system, one of said parts being a paste consisting of a binder system comprising a colourless binder monomer which is a bisphenol A derivative having at least two terminal acrylate or methacrylate ester groups, at least 65% by weight of a finely divided filler and a free radical polymerization catalyst; and the other of said parts being a paste containing substantially the same monomer as in the first part, at least 65% by weight of a finely divided filler and an activator for said catalyst. Polymerization is initiated when the two packaged parts are blended together. The preferred binder monomer is that of the formula The viscosity of the monomer can be adjusted by diluting with another monomer such as methyl methacrylate or a glycol dimethacrylate, e.g. triethylene glycol dimethacrylate. Benzoyl peroxide is a suitable catalyst and the activator may be, for example, N,N.dimethyl.p-toluidine or p-toluenesulphinic acid. Preferred as fillers are inorganic materials such as fused silica, aluminium oxide, crystalline quartz and glass beads. The filler may be treated with a keying agent, e.g. an ethylenically unsaturated organosilane, to improve the bond between the polymerized binder and the filler particles. Optional components which may be added include inhibitors such as butylated hydroxy-toluene, U.V. absorbers such as 2-hydroxy-4-methoxy-benzophenone, and submicron particle material, e.g. hydrophobic submicron silica, to prevent possible slight separation between binder monomer and filler. Pigment can be included in one of the parts to obtain any desired colour shade; in the example unspecified organic dyes are used.
During the organic phase, participants are asked to follow strictly the two 20-day organic dietary menus provided to them for 40 days. The organic dietary menus were prepared by a certified dietitian. The meals of the organic phase are prepared by a certified organic restaurant and are delivered to school every day except Sunday. For the meals of breakfast and afternoon snacks, children choose their preferred options for the week on the Friday of the previous week according to a list of organic food items and the products for these meals are delivered on Saturday along with the rest meals. Parents are responsible to pick-up the organic meals from school and ensure that the participating children have access to them.
The present invention relates in essence to a method for detecting a subset of cells with a binding domain which is specific for a target which characterizes said subset of cells, which method comprises detecting, ex vivo, said subset of cells, wherein said binding domain is to be administered to a subject which comprises or is assumed to comprise said subset of cells, prior to the removal of said subset of cells. The present invention also relates to the use of a binding domain as defined herein in a method defined herein. The use of a binding domain as defined herein for the preparation of a diagnostic composition to be used in a method defined herein is also envisaged. In another aspect, the present invention relates to the binding domain as defined herein to be used in a method defined herein. Kits comprising a binding domain as defined herein and means to administer said binding domain to a subject, and, optionally, means to detect said binding domain with a method defined herein, are also disclosed. In another aspect, the present invention relates to the use of a binding domain, preferably a therapeutically effective antibody like for example alemtuzumab, apolizumab, cetuximab, epratuzumab, galiximab, gemtuzumab, ipilimumab, labetuzumab, panitumumab, rituximab, trastuzumab, nimotuzumab, mapatumumab, matuzumab, rhMab ICR62, rhMab B-Ly1 and pertuzumab etc including combinations thereof, for the preparation of a pharmaceutical composition for the treatment of patients disposed to respond favorably to said binding domain as identified by a method defined herein.
Butorphanol Tartrate Nasal Spray should be prescribed only by healthcare professionals who are knowledgeable about the use of opioids and how to mitigate the associated risks.

Use the lowest effective dosage for the shortest duration of time consistent with individual patient treatment goals [see WARNINGS]. Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of Butorphanol Tartrate Nasal Spray for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks.

Many acute pain conditions (e.g., the pain that occurs with a number of surgical procedures or acute musculoskeletal injuries) require no more than a few days of an opioid analgesic. Clinical guidelines on opioid prescribing for some acute pain conditions are available.

There is variability in the opioid analgesic dose and duration needed to adequately manage pain due both to the cause of pain and to individual patient factors. Initiate the dosing regimen for each patient individually, taking into account the patient’s underlying cause and severity of pain, prior analgesic treatment and response, and risk factors for addiction, abuse, and misuse [see WARNINGS]. 

Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with Butorphanol Tartrate Nasal Spray. Consider this risk when selecting an initial dose and when making dose adjustments [see WARNINGS].
Following the visualization of the anatomical structures, the nerve block needle will be advanced via the in-plane technique above the serratus anterior muscles until the interfascial space was reached. After hydrodissection with 2 ml normal saline, 20 ml 0.25% bupivacaine will be injected into the area.
FIELD: medicine. SUBSTANCE: method involves carrying out surgical or mechanical cleaning of the wound (tampons wetted with 10-20% solution of vegetable extraction are useable in mechanical treatment), applying sterile bandage on the wound. 10-20% solution of vegetable extraction is useable as antiseptic agent for impregnating bandages. Bandaging is to be done each second day, bandages are changed 5-6 times during the course. Bandaging is combined with laser treatment applied to the wound. The vegetable extraction is produced by processing raw vegetable materials like herb or hay of lucerne with vapor-condensate extractant containing microelement mixture in mg/kg of vegetable mass: Mo-8.0, Ba-10.0, Pb-20.0, Co-1.05, V-1.0, Cs-0.5, Zn-200.0, Fe-300.0, Sn-40.0. EFFECT: enhanced effectiveness of treatment course.
Participants in stratum S1 will undergo standard dose craniospinal radiation with boost to the primary tumor site once daily 5 days a week for 6 weeks. Six weeks after completion of radiotherapy, patients receive one cycle of chemotherapy (cisplatin, vincristine, cyclophosphamide) once every 4 weeks for 4 cycles in absence of unacceptable toxicity. After completion of 4 cycles of chemotherapy, participants who are skeletally mature will receive maintenance chemotherapy with vismodegib. Some participants will complete aerobic training and/or neurocognitive remediation.
The primary cilium behaves as a platform for sensing and integrating extracellular cues to control a plethora of cellular activities. However, the functional interaction of this sensory organelle with epithelial-mesenchymal transition (EMT) during pulmonary fibrosis remains unclear. Here, we reveal a critical role for cylindromatosis (CYLD) in reciprocally linking the EMT program and ciliary homeostasis during pulmonary fibrosis. A close correlation between the EMT program and primary cilia is observed in bleomycin-induced pulmonary fibrosis as well as TGF-β-induced EMT model. Mechanistic study reveals that downregulation of CYLD underlies the crosstalk between EMT and ciliary homeostasis by inactivating histone deacetylase 6 (HDAC6) during pulmonary fibrosis. Moreover, manipulation of primary cilia is an effective means to modulate the EMT program. Collectively, these results identify a pivotal role for the CYLD/HDAC6 signaling in regulating the reciprocal interplay between the EMT program and ciliary homeostasis during pulmonary fibrosis.
1,000,280. Spray drying of solutions or suspensions of solids in liquids. MICROBIOLOGICALS Ltd. June 24, 1963 [July 6, 1962], No. 25961/62. Headings B1B and B2F. [Also in Division A2] Solutions and suspensions of solids in liquids are dried by spraying the solution or suspension by means of an atomizer 35 into a chamber 21 where the droplets are exposed to radiant heat from infra-red heaters 25 spaced around the internal wall of the chamber, while cool air is drawn into the chamber through filters in floor 16 above the atomizer. The dried particles flow out of the collecting chamber 22 through rotary valve 23 on to a belt conveyer 28. The drying chamber is assembled from stainless steel panels 12. Banks of heater boxes 24 are mounted on the inner surface of the panels 12. Each box 24 contains eight infra-red heaters which are advantageously 400-watt glazed ceramic trough elements with wavelengths in the range of 2À5-7À5Á. Within the lower end of chamber 21, just above the mouth of collecting chamber 22, is located a cyclone which is connected by pipe 27a to an extractor fan. Moist air is withdrawn from the drying chamber through this cyclone ; and any entrained solid particles are separated from the air and returned to the mouth of the collecting chamber. The solution or suspension to be dried is pumped to atomizer 35 through a pipe 34 by a metering pump 33. The atomizer, Fig. 9, comprises a double-walled spinner 36, which is of 6-9 inches diameter and is supported on the bottom end of a shaft 37, the top of which is locked on a pulley 41. The atomizer is driven, at shaft speeds of from 3000-10,000 r.p.m., by an electric motor and a driving belt 40. The liquid passes to the spinner 36 from pipe 34 via a duct 45 in adaptor 44 and an annular passage 46 which opens into a cavity 47 between the two conical walls of the spinner. This cavity terminates in an annular discharge orifice 48 from which the liquid emerges into the drying chamber in a cloud of fine droplets. Examples are given relating to the drying of (1) aqueous glucose, (2) corn steep liquor, (3) liquid egg, and (4) an aqueous solution of polyvinyl alcohol emulsified with Vitamin A palmitate.